Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2006

Generic Version of Colestid Tablets Will Come to Market

  • Impax Laboratories has been granted approval for its generic version of Colestid® tablets (Colestipol Hydrochloride Tablets) 1 gram. Pharmacia and Upjohn Company (Pfizer) markets these tablets as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia who haven’t responded adequately to diet.

    Impax will be able to tap into brand Colestid sales, which reached $20 million for the 12 months ended August 31, 2006, in the U.S., according to Wolters Kluwer Health. The company has 180-day market exclusivity for this product as it received first-to-file status.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »